Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases

Journal of Cancer Science and Therapy

Volumn 4, Issue 3, 2012, Pages 31-42

  Kanwar, Jagat R ^a   Samarasinghe, Rasika M ^a   Sehgal, Rakesh ^b   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cancer; Infammation; Infection; Lactoferrin; Nanodelivery; Oral administration

Indexed keywords

CISPLATIN; CYCLODEXTRIN; DOCETAXEL; DOXORUBICIN; GADOLINIUM; LACTOFERRIN; METHOTREXATE; NANOPARTICLE; PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TECHNETIUM 99M; TETRANDRINE; VERAPAMIL;

ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN CANCER; BRAIN CELL; CANCER DIAGNOSIS; CANCER REGRESSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; EDEMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; IRON TRANSPORT; ISOTOPE LABELING; MELANOMA; NANOTECHNOLOGY; NEOPLASM; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RECEPTOR BINDING; SKIN FIBROSIS;

EID: 84859873180     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000107     Document Type: Article

References (154)

1. Uttley AH, Collins CH, Naidoo J, George RC (1988) Vancomycin-resistant enterococci. Lancet 1: 57-58.
2. Benner EJ, Morthland V (1967) Methicillin-resistant Staphylococcus aureus. Antimicrobial susceptibility. N Engl J Med 277: 678-680.
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738.
4. Soerensen M, Soerensen SP (1939) The proteins in whey. CR Trav Lab Carlsberg 23: 55-99.
5. Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, et al. (1984) Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 145: 659-676.
6. Baker HM, Baker EN (2004) Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals 17: 209-216.
7. Teng CT, Beard C, Gladwell W (2002) Differential expression and estrogen response of lactoferrin gene in the female reproductive tract of mouse, rat, and hamster. Biol Reprod 67: 1439-1449.
8. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, et al. (2008) Lactoferrin structure and functions. Adv Exp Med Biol 606: 163-194.
9. Baker EN, Baker HM (2009) A structural framework for understanding the ultifunctional character of lactoferrin. Biochimie 91: 3-10.
10. Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16: 87-96.
11. Ward PP, Paz E, Conneely OM (2005) Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 62: 2540-2548.
12. Saarinen UM, Siimes MA, Dallman PR (1977) Iron absorption in infants: high bioavailability of breast milk iron as indicated by the extrinsic tag method of iron absorption and by the concentration of serum ferritin. J Pediatr 91: 36-39.
13. Lönnerdal B, Bryant A (2006) Absorption of iron from recombinant human lactoferrin in young US women. The Am J Clin Nutr 83: 305-309.
14. Paesano R, Torcia F, Berlutti F, Pacifci E, Ebano V, et al. (2006) Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol 84: 377-380.
15. Suzuki YA, Lopez V, Lönnerdal B (2005) Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 62: 2560-2575.
16. Van Snick JL, Masson PL (1976) The binding of human lactoferrin to mouse peritoneal cells. J Exp Med 144: 1568-1580.
17. Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, et al. (1997) The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. Biochem J 327: 841-846.
18. Mann DM, Romm E, Migliorini M (1994) Delineation of the glycosaminoglycan-binding site in the human infammatory response protein lactoferrin. J Biol Chem 269: 23661-23667.
19. van Berkel PH, Geerts ME, van Veen HA, Mericskay M, de Boer HA, et al. (1997) N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J 328: 145-151.
20. Strickland DK, Gonias SL, Argraves WS (2002) Diverse roles for the LDL receptor family. Trends Endocrinol Metab 13: 66-74.
21. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J (1992) Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 267: 26172-26180.
22. Bennatt DJ, Ling YY, McAbee DD (1997) Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. Biochemistry 36: 8367-8376.
23. Bennett RM, Kokocinski T (1979) Lactoferrin turnover in man. Clin Sci (Lond) 57: 453-460.
24. Goretzki L, Mueller BM (1998) Low-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein. Biochemical J 336: 381-386.
25. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaïssa M, et al. (1999) Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 274: 7011-7017.
26. Grey A, Banovic T, Zhu Q, Watson M, Callon K, et al. (2004) The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 18: 2268-2278.
27. Brandl N, Zemann A, Kaupe I, Marlovits S, Huettinger P, et al. (2010) Signal transduction and metabolism in chondrocytes is modulated by lactoferrin. Osteoarthritis Cartilage 18: 117-125.
28. Cox TM, Mazurier J, Spik G, Montreuil J, Peters TJ (1979) Iron binding proteins and infux of iron across the duodenal brush border. Evidence for specifc lactotransferrin receptors in the human intestine. Biochim Biophys Acta 588: 120-128.
29. Ashida K, Sasaki H, Suzuki YA, Lönnerdal B (2004) Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals 17: 311-315.
30. Jiang R, Lönnerdal B (2012) Apo- and holo-lactoferrin stimulate proliferation of mouse crypt cells but through different cellular signaling pathways. Int J Biochem Cell Biol 44: 91-100.
31. Jiang R, Lopez V, Kelleher SL, Lönnerdal B (2011) Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226: 3022-3031.
32. Gupta I, Sehgal R, Kanwar RK, Sehgal A, Kanwar JR (2009) Recent advances of metal binding protein lactoferrin as an anti-microbial agent. Curr Bioactive Comp 5: 226-233.
33. Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, et al. (2008) 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immun Cell Bio 86: 277-288.
34. Arnold RR, Cole MF, McGhee JR (1977) A bactericidal effect for human lactoferrin. Science 197: 263-265.
35. Brock JH (2002) The physiology of lactoferrin. Biochem Cell Biol 80: 1-6.
36. Zagulski T, Lipiński P, Zagulska A, Jarzabek Z (1998) Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int J Exp Pathol 79: 117-123.
37. Diarra MS, Petitclerc D, Lacasse P (2002) Effect of lactoferrin in combination with penicillin on the morphology and the physiology of Staphylococcus aureus isolated from bovine mastitis. J Dairy Sci 85: 1141-1149.
38. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG (2002) Lactoferrin protects rabbits from Shigella fexneri-induced infammatory enteritis. Infect Immun 70: 7050-7053.
39. Mosquito S, Ochoa TJ, Cok J, Cleary TG (2010) Effect of bovine lactoferrin in Salmonella ser. Typhimurium infection in mice. Biometals 23: 515-521.
40. Wada T, Aiba Y, Shimizu K, Takagi A, Miwa T, et al. (1999) The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Scand J Gastroenterol 34: 238-243.
41. Dial EJ, Lichtenberger LM (2002) Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 80: 113-117.
42. Dial EJ, Romero JJ, Headon DR, Lichtenberger LM (2000) Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol 52: 1541-1546.
43. Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T, et al. (2009) Twenty-fve years of research on bovine lactoferrin applications. Biochimie 91: 52-57.
44. Di Mario F, Aragona G, Dal Bǒ N, Cavestro GM, Cavallaro L, et al. (2003) Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 35: 706-710.
45. Guttner Y, Windsor HM, Viiala CH, Marshall BJ (2003) Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther 17: 125-129.
46. Kanwar JR, Kanwar RK, Sun X, Punj V, Matta H, et al. (2009) Molecular and biotechnological advances in milk proteins in relation to human health. Curr Protein Pept Sci 10: 308-338.
47. Kanwar RK, Singh N, Gurudevan S, Kanwar JR (2011) Targeting hepatitis B virus and human papillomavirus induced carcinogenesis: novel patented therapeutics. Recent Pat Antiinfect Drug Discov 6: 158-174.
48. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, et al. (2005) Lactoferrin prevents dendritic cell-mediated human immunodefciency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol 79: 3009-3015.
49. Carthagena L, Becquart P, Hocini H, Kazatchkine MD, Bouhlal H, et al. (2011) Modulation of HIV Binding to Epithelial Cells and HIV Transfer from Immature Dendritic Cells to CD4 T Lymphocytes by Human Lactoferrin and its Major Exposed LF-33 Peptide. Open Virol J 5: 27-34.
50. Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, et al. (1998) Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245: 549-553.
51. Kaito M, Iwasa M, Fujita N, Kobayashi Y, Kojima Y, et al. (2007) Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J Gastroenterol Hepatol 22: 1894-1897.
52. Marchetti M, Trybala E, Superti F, Johansson M, Bergström T (2004) Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318: 405-413.
53. Pietrantoni A, Di Biase AM, Tinari A, Marchetti M, Valenti P, et al. (2003) Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother 47: 2688-26891.
54. Pietrantoni A, Dofrelli E, Tinari A, Ammendolia MG, Puzelli S, et al. (2010) Bovine lactoferrin inhibits infuenza A virus induced programmed cell death in vitro. Biometals 23: 465-475.
55. Cirioni O, Giacometti A, Barchiesi F, Scalise G (2000) Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46: 577-582.
56. León-Sicairos N, López-Soto F, Reyes-López M, Godínez-Vargas D, Ordaz-Pichardo C, et al. (2006) Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme. Clin Med Res 4: 106-113.
57. León-Sicairos N, Reyes-López M, Canizalez-Román A, Bermúdez-Cruz RM, Serrano-Luna J, et al. (2005) Human hololactoferrin: endocytosis and use as an iron source by the parasite Entamoeba histolytica. Microbiology 151: 3859-3871.
58. Bansal D, Bhatti HS, Sehgal R (2005) Role of cholesterol in parasitic infections. Lipids Health Dis 4: 10.
59. López-Soto F, León-Sicairos N, Nazmi K, Bolscher JG, de la Garza M (2010) Microbicidal effect of the lactoferrin peptides lactoferricin17-30, lactoferrampin265-284, and lactoferrin chimera on the parasite Entamoeba histolytica. Biometals 23: 563-568.
60. Lima MF, Kierszenbaum F (1987) Lactoferrin effects on the interaction of blood forms of Trypanosoma cruzi with mononuclear phagocytes. Int J Parasitol 17: 1205-1208.
61. Fritsch G, Sawatzki G, Treumer J, Jung A, Spira DT (1987) Plasmodium falciparum: inhibition in vitro with lactoferrin, desferriferrithiocin, and desferricrocin. Exp Parasitol 63: 1-9.
62. Turchany JM, Aley SB, Gillin FD (1995) Giardicidal activity of lactoferrin and N-terminal peptides. Infect Immun 63: 4550-4552.
63. Ochoa TJ, Chea-Woo E, Campos M, Pecho I, Prada A, et al. (2008) Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children. Clin Infect Dis 46: 1881-1883.
64. Sinnis P, Willnow TE, Briones MR, Herz J, Nussenzweig V (1996) Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J Exp Med 184: 945-954.
65. Eda S, Eda K, Prudhomme JG, Sherman IW (1999) Inhibitory activity of human lactoferrin and its peptide on chondroitin sulfate A-, CD36-, and thrombospondin-mediated cytoadherence of plasmodium falciparum-infected erythrocytes. Blood 94: 326-332.
66. Isamida T, Tanaka T, Omata Y, Yamauchi K, Shimazaki K, et al. (1998) Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J Vet Med Sci 60: 241-244.
67. Leitch GJ, Ceballos C (2009) A role for antimicrobial peptides in intestinal microsporidiosis. Parasitology 136: 175-181.
68. Nakao K, Imoto I, Gabazza EC, Yamauchi K, Yamazaki N, et al. (1997) Gastric juice levels of lactoferrin and Helicobacter pylori infection. Scand J Gastroenterol 32: 530-534.
69. Venge P, Foucard T, Henriksen J, Håkansson L, Kreuger A (1984) Serum-levels of lactoferrin, lysozyme and myeloperoxidase in normal, infection-prone and leukemic children. Clin Chim Acta 136: 121-130.
70. Defer MC, Dugas B, Picard O, Damais C (1995) Impairment of circulating lactoferrin in HIV-1 infection. Cell Mol Biol (Noisy-le-grand) 41: 417-421.
71. Bezault J, Bhimani R, Wiprovnick J, Furmanski P (1994) Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54: 2310-2312.
72. Mader JS, Salsman J, Conrad DM, Hoskin DW (2005) Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 4: 612-624.
73. Fujita K, Matsuda E, Sekine K, Iigo M, Tsuda H (2004) Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Carcinogenesis 25: 1961-1966.
74. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S (2001) Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 91: 236-240.
75. Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, et al. (1999) Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 74: 486-498.
76. Xiao Y, Monitto CL, Minhas KM, Sidransky D (2004) Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 10: 8683-8686.
77. Oh SM, Pyo CW, Kim Y, Choi SY (2004) Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene 23: 8282-8291.
78. Kanwar RK, Kanwar R (2011) Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein Pept Lett.
79. Iigo M, Kuhara T, Ushida Y, Sekine K, Moore MA, et al. (1999) Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis 17: 35-40.
80. Varadhachary A, Wolf JS, Petrak K, O'Malley BW Jr, Spadaro M, et al. (2004) Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 111: 398-403.
81. Iigo M, Alexander DB, Long N, Xu J, Fukamachi K, et al. (2009) An Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 91: 86-101.
82. Kanwar JR, Haggarty NW, Palmano KP, Krissansen GW (2005) Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer.
83. Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, et al. (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38: 192-199.
84. Wolf JS, Li G, Varadhachary A, Petrak K, Schneyer M, et al. (2007) Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res 13: 1601-1610.
85. Rossiello R, Carriero MV, Giordano GG (1984) Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol 37: 51-55.
86. Panella TJ, Liu YH, Huang AT, Teng CT (1991) Polymorphism and altered methylation of the lactoferrin gene in normal leukocytes, leukemic cells, and breast cancer. Cancer Res 51: 3037-3043.
87. Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, et al. (1994) Immunochemical detection of human lactoferrin in feces as a new marker for infammatory gastrointestinal disorders and colon cancer. Clin Biochem 27: 259-264.
88. Hirata I, Hoshimoto M, Saito O, Kayazawa M, Nishikawa T, et al. (2007) Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 13: 1569-1574.
89. Walmer DK, Padin CJ, Wrona MA, Healy BE, Bentley RC, et al. (1995) Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. Cancer Res 55: 1168-1175.
90. Benaïssa M, Peyrat JP, Hornez L, Mariller C, Mazurier J, et al. (2005) Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int J Cancer 114: 299-306.
91. Farley J, Loup D, Nelson M, Mitchell A, Esplund G, et al. (1997) Neoplastic transformation of the endocervix associated with downregulation of lactoferrin expression. Mol Carcinog 20: 240-250.
92. Gregoriadis G (1973) Drug entrapment in liposomes. FEBS letters 36: 292-296.
93. Kramer PA (1974) Letter: Albumin microspheres as vehicles for achieving specifcity in drug delivery. J Pharm Sci 63: 1646-1647.
94. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R (2010) Applications of aptamers in nanodelivery systems in cancer, eye and infammatory diseases. Nanomedicine (Lond) 5: 1435-1445.
95. Choe TB, Park IC, Hong SI (1998) Enhancement of cationic liposome-mediated transfection by lactoferrin. Biotechnol Tech 12: 577-581.
96. Takeuchi T, Jyonotsuka T, Kamemori N, Kawano G, Shimizu H, et al. (2006) Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp Physiol 91: 1033-1040.
97. Gupta AK, Curtis AS (2004) Lactoferrin and ceruloplasmin derivatized superparamagnetic iron oxide nanoparticles for targeting cell surface receptors. Biomaterials 25: 3029-3040.
98. Kanwar JR, Mahidhara G, Kanwar RK (2011) A novel alginate enclosed chitosan-calcium phosphate- loaded iron saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer. Nanomedicine In Press.
99. Baratchi S, Kanwar RK, Khoshmanesh K, Vasu P, Ashok C, et al. (2009) Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases. Curr Nanosci 5: 15-25.
100. Huang R, Ke W, Han L, Liu Y, Shao K, et al. (2009) Brain-targeting mechanisms of lactoferrin-modifed DNA-loaded nanoparticles. J Cereb Blood Flow Metab 29: 1914-1923.
101. Kanwar JR, Sun X, Punj V, Sriramoju B, Mohan RR, et al. (2011) Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fre power to heal. Nanomedicine [Epub ahead of print].
102. Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, et al. (1979) Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 64: 684-688.
103. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P (2005) Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int J Pharm 298: 274-292.
104. de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47: 323-355.
105. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, et al. (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10: 3667-3677.
106. Vinogradov SV, Batrakova EV, Kabanov AV (2004) Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 15: 50-60.
107. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL (1993) Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. American J Pathol 142: 1574-1585.
108. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, et al. (1996) Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91: 566-572.
109. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, et al. (1994) The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650: 20-31.
110. Siebert PD, Huang BC (1997) Identifcation of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci USA 94: 2198-2203.
111. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, et al. (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 92: 9603-9607.
112. Huang R, Ke W, Liu Y, Jiang C, Pei Y (2008) The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29: 238-246.
113. Huang R, Ke W, Han L, Liu Y, Shao K, et al. (2010) Lactoferrin-modifed nanoparticles could mediate effcient gene delivery to the brain in vivo. Brain Res Bull 81: 600-604.
114. Silbergeld DL, Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86: 525-531.
115. Pang Z, Feng L, Hua R, Chen J, Gao H, et al. (2010) Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 7: 1995-2005.
116. Chen H, Qin Y, Zhang Q, Jiang W, Tang L, et al. (2011) Lactoferrin modifed doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci 44: 164-173.
117. Kanwar JR, Singh N, Kanwar RK (2011) Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine (Lond) 6: 701-714.
118. Roseanu A, Florian PE, Moisei M, Sima LE, Evans RW, et al. (2010) Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells. Biometals 23: 485-492.
119. Onishi H, Koyama K, Sakata O, Machida Y (2010) Preparation of chitosan/ alginate/calcium complex microparticles loaded with lactoferrin and their effcacy on carrageenan-induced edema in rats. Drug Dev Ind Pharm 36: 879-884.
120. Onishi H, Machida Y, Koyama K (2007) Preparation and in vitro characteristics of lactoferrin-loaded chitosan microparticles. Drug Dev Ind Pharm 33: 641-647.
121. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EK, Nibbering PH (2000) Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile infammations. Eur J Nucl Med 27: 292-301.
122. Welling MM, Lupetti A, Balter HS, Lanzzeri S, Souto B, et al. (2001) 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 42: 788-794.
123. Welling MM, Nibbering PH, Paulusma-Annema A, Hiemstra PS, Pauwels EK, et al. (1999) Imaging of bacterial infections with 99mTc-labeled human neutrophil peptide-1. J Nucl Med 40: 2073-2080.
124. Koyama K, Onishi H, Sakata O, Machida Y (2009) Preparation and in vitro evaluation of chitosan-coated alginate/calcium complex microparticles loaded with fuorescein-labeled lactoferrin. Yakugaku Zasshi 129: 1507-1514.
125. Pan D, Caruthers SD, Hu G, Senpan A, Scott MJ, et al. (2008) Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 130: 9186-9187.
126. Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, et al. (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168: 297-301.
127. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, et al. (1990) Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 175: 489-493.
128. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, et al. (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 152: 167-173.
129. Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, et al. (2011) Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specifc MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32: 495-502.
130. Sahu SC, Casciano DA (Eds) (2009) Nanotoxicity. Nanotoxicity: from in vivo and in vitro models to health risks, John Wiley & Sons Ltd: West Sussex, UK.
131. Nel A, Xia T, Madler L, Li N (2006) Toxic potential of materials at the nanolevel. Science 311: 622-627.
132. Huang X, Peng X, Wang Y, Shin DM, El-Sayed MA, et al. (2010) A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano 4: 5887-5896.
133. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, et al. (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65: 5317-5324.
134. Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20: 417-422.
135. Riviere K, Huang Z, Jerger K, Macaraeg N, Szoka FC Jr (2011) Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration. J Drug Target 19: 14-24.
136. Leamon CP, Cooper SR, Hardee GE (2003) Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14: 738-747.
137. Zhang Y, Zhang J (2005) Surface modifcation of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J Colloid Interface Sci 283: 352-357.
138. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, et al. (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672.
139. Farokhzad OC, Cheng J, Teply BA, Sherif I, Jon S, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320.
140. Choi CH, Alabi CA, Webster P, Davis ME (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107: 1235-1240.
141. Wu J, Lu Y, Lee A, Pan X, Yang X, et al. (2007) Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10: 350-357.
142. Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14: 1122-1132.
143. Sahoo SK, Ma W, Labhasetwar V (2004) Effcacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112: 335-340.
144. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740.
145. Pan X, Wu G, Yang W, Barth RF, Tjarks W, et al. (2007) Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconj Chem 18: 101-108.
146. Tseng CL, Wang TW, Dong GC, Yueh-Hsiu Wu S, et al. (2007) Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28: 3996-4005.
147. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, et al. (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105: 9343-9348.
148. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, et al. (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 140: 166-173.
149. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407.
150. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, et al. (2004) cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl 43: 6323-6327.
151. Gosk S, Moos T, Gottstein C, Bendas G (2008) VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 1778: 854-863.
152. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, et al. (2006) LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 99: 163-176.
153. Banerjee R, Tyagi P, Li S, Huang L (2004) Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 112: 693-700.
154. Physorg-Instablogs Network (2007), viewed March 6 2012, http://www.scienceahead.com/entry/now-remote-controlled-nanoparticles-to-treat-tumors-directly-on-location/.